SAN DIEGO, April 25, 2011 /PRNewswire/ -- Pharmatek Laboratories, Inc., a premier contract development and manufacturing organization supporting the pharmaceutical industry, announced that it has added spray drying to its drug formulation and manufacturing capabilities. The company has purchased a Buchi B-290 Mini Spray Dryer for formulation feasibility studies and small-scale clinical manufacture. This technology can be used for both oral and parenteral dosage forms.
"Spray drying is an integral technology in Pharmatek's toolkit for formulating insoluble compounds. The high degree of control and reduced process steps afforded by this process offer a number of advantages over other formulation techniques: enhanced robustness and reproducibility, and the ability to control and create uniform particle size and stabilize volatile and thermo-sensitive compounds," stated Jeffrey Bibbs, CEO and CSO of Pharmatek.
In addition to converting liquid solutions or suspensions into solids in a single process step, spray drying allows for swift and efficient coating of particles, creating matrices of drug and polymers (spray dried dispersion), and manufacturing of microcapsules.
"Adding spray drying to our drug development toolkit provides another degree of sophistication to Pharmatek's broad array of formulation technologies and equipment," continued Tim Scott, President of Pharmatek. "In the end, it is all about offering our clients another approach to formulating and manufacturing their insoluble compounds."
For a complete listing of Pharmatek's equipment and capabilities, please visit www.pharmatek.com.
About Pharmatek Laboratories, Inc.
Pharmatek Laboratories, Inc. is a premier pharmaceutical chemistry development company providing full-service pharmaceutical chemistry product development for the pharmaceutical industry. Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, stability storage and testing, and cytotoxic and high-potency development.
Statements contained in this media release which are not historical facts may constitute forward-looking statements. All forward-looking statements are subject to risks and uncertainties which could cause actual results to differ from those projected including sales forecasts and strategic expansion. The trademarks Pharmatek, Pharmatek Laboratories, Inc., Hot Rod Chemistry, Pharmatek Formulation Screening, Pharmatek University and PTEK U are all property of Pharmatek Laboratories, Inc. Additional information about Pharmatek Laboratories may be obtained at the Web site http://www.pharmatek.com or by calling 858-805-6383.
Ryan Lane, Marketing Associate
Pharmatek Laboratories, Inc.
(858) 805-6383 x284
SOURCE Pharmatek Laboratories, Inc.